HI Bio Reaches For The Lead With Phase II Primary Membranous Nephropathy Data
While Roche is in Phase III with Gazyva, HI-Bio thinks its autoantibody-depleting mechanism may be the best approach in PMN.
You may also be interested in...
Private Company Edition: TCGX raises $1bn for its second fund, Goldman Sachs’ first fund totals $650m and Panlin’s biopharma fund grows. Also, Apollo’s series C increases to $260m, Avistone closes a $140m series B, OnCusp raises a $100m series A and HI-Bio grabs $95m in series B cash.
Buying Chinook will add a pair of late-stage programs to Novartis's IgAN portfolio which is currently headed by iptacopan but the proposed deal could attract the attention of the FTC.
Human Immunology Biosciences (HI-Bio) launched with $120m and two candidates from MorphoSys, including the CD38 inhibitor felzartamab already in the clinic for immune-mediated kidney diseases.